A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

3상 진행 중(모집 완료) NCT05171647

요약

This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).

Objective Response Rate (ORR) as Determined by the Independent Review Facility (IRF), According to Lugano Response Criteria 2014 (LRC) Using Positron Emission Tomography-computed Tomography (PET-CT) or CT Scans in Interim Analysis Population (IAP)

Up to approximately 23.8 months · percentage of participants

Progression-free Survival (PFS) as Determined by the IRF, According to LRC Using PET-CT or CT Scans

Up to 32 months · months

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

• Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diag — National Cancer Institute (NCI)
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating — National Cancer Institute (NCI)
• Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Tr — National Cancer Institute (NCI)
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibruti — National Cancer Institute (NCI)
• An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymph — Acerta Pharma BV
• Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituxim — National Cancer Institute (NCI)

전체 임상